| Title |
Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome
|
|---|---|
| Published in |
PLOS ONE, October 2012
|
| DOI | 10.1371/journal.pone.0047805 |
| Pubmed ID | |
| Authors |
Saskia M. Rombach, Johannes M. F. G. Aerts, Ben J. H. M. Poorthuis, Johanna E. M. Groener, Wilma Donker-Koopman, Erik Hendriks, Mina Mirzaian, Sijmen Kuiper, Frits A. Wijburg, Carla E. M. Hollak, Gabor E. Linthorst |
| Abstract |
Enzyme replacement therapy (ERT) with alpha-Galactosidase A (aGal A) may cause antibody (AB) formation against aGal A in males with Fabry disease (FD). Anti agalsidase ABs negatively influence globotriaosylceramide (Gb3) reduction. We investigated the impact of agalsidase AB on Gb3 and lysoGb3 and clinical outcome in Fabry patients on ERT. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 1% |
| Unknown | 90 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 19% |
| Student > Ph. D. Student | 14 | 15% |
| Other | 9 | 10% |
| Student > Master | 7 | 8% |
| Student > Bachelor | 6 | 7% |
| Other | 13 | 14% |
| Unknown | 25 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 29% |
| Biochemistry, Genetics and Molecular Biology | 8 | 9% |
| Agricultural and Biological Sciences | 7 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Chemistry | 3 | 3% |
| Other | 14 | 15% |
| Unknown | 29 | 32% |